Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05784038 |
Recruitment Status :
Not yet recruiting
First Posted : March 24, 2023
Last Update Posted : March 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Monkeypox MPOX | Diagnostic Test: Viral genomic Diagnostic Test: Untargeted Metabolomics |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 80 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Months |
Official Title: | Observational, Prospective, Cohort Study of Mpox Infection in Brazil - NETPOX Cohort |
Estimated Study Start Date : | April 1, 2023 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | December 2023 |
Group/Cohort | Intervention/treatment |
---|---|
Human cases of monkeypox confirmed by PCR
Laboratory-confirmed mpox infection is defined as determined by polymerase chain reaction assay (PCR), culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 5 days of inclusion.
|
Diagnostic Test: Viral genomic
Evaluation of mpox viral genomic Diagnostic Test: Untargeted Metabolomics Evaluation of metabolomics of the total plasma, oropharynx, and skin samples. |
- Composed of incidence of rash, fever, adenopathy, general pain, chills, weakness, occurrence of hospitalization, and neurological repercussions [ Time Frame: Up to 90 days after the inclusion ]symptoms' incidence in participants with mpox infection
- Death [ Time Frame: Up to 90 days after the inclusion ]Incidence of death
- Hospitalizations [ Time Frame: Days 15, 30, 60, and 90 ]Incidence of hospitalization
- Untargeted metabolomics of total plasmas and skin lesion [ Time Frame: Days 15, 30, 60, and 90 ]Changes among visits of Immune-metabolomics responses related to symptoms' incidence
- Viral genomic [ Time Frame: Day 0 ]Evaluation of the pattern of viral genome of the mpox virus circulation in Brazil
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men and women aged ≥ 18 years with confirmed MPOX infection.
(laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization)
Exclusion Criteria:
- Inability to provide informed consent;
- Patient who, judging by the study team, does not have a condition for decentralized follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05784038
Contact: Henrique AR Fonseca, PhD | +5511968308958 | henrique.fonseca@einstein.br | |
Contact: Diogo Moia, PharmD | diogo.moia@einstein.br |
Study Chair: | Henrique Fonseca | Hospital Albert Einstein |
Responsible Party: | Hospital Israelita Albert Einstein |
ClinicalTrials.gov Identifier: | NCT05784038 |
Other Study ID Numbers: |
NETPOX |
First Posted: | March 24, 2023 Key Record Dates |
Last Update Posted: | March 24, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Mpox (monkeypox) Infections Poxviridae Infections DNA Virus Infections Virus Diseases |